BAYER AG NA O.N.
Commented by Fabian Lorenz on July 29th, 2025 | 07:15 CEST
Watch out for BioNTech! Bayer, Formycon, and Vidac Pharma shares are on the rise!
While all eyes appear to be on BioNTech's upcoming quarterly results on August 4, other shares are on the rise. Analysts see strong upside potential for Vidac Pharma, citing the possibility of a multi-fold increase. The Company has appointed a new CEO, and its listing on a major German stock exchange is expected soon. This is an exciting mix that could break the sideways trend and ignite a rally. Bayer and Formycon have already shown that a 50% increase is possible in just a few months. However, the DAX-listed company had to report a delay in product approval last Friday. At Formycon, the upward trend is still intact. Analysts praise the progress made in biosimilar development.
Read
Commented by André Will-Laudien on July 28th, 2025 | 07:15 CEST
Better than Nvidia and without AI – 185% with Veganz, Bayer, Novo Nordisk, and Nestlé in focus
It does not always have to be NVIDIA. German stocks are also performing well. Those who took advantage of Trump's tariff panic in April to buy in have since earned 75% with NVIDIA, but a whopping 185% with German plant-based nutrition expert, Veganz Group. Even the long-sidelined pharmaceutical giant Bayer has made an astonishing comeback with 50% growth, while Nestlé, supposedly an anchor in many portfolios, has lost 15%. Some call it selection luck, while others refer to it as sector rotation. It is currently apparent that the long, strong rally on international stock markets is benefiting only a few stocks. It remains fascinating that the stock market always celebrates when Donald Trump's tariff threats ultimately turn out to be less severe than initially expected. What remains for the economy, however, is less growth and high prices at the checkout. The new US policy stands for many things, but first and foremost, for less trade and economic downturn. How can investors still profit?
Read
Commented by Nico Popp on July 21st, 2025 | 07:15 CEST
A turning point in German healthcare! Are we moving closer to the US model? PanGenomic Health, Bayer, and Nestlé
Are US-style conditions soon coming to Germany? Health economist Jürgen Wasem is calling for greater patient cost-sharing. Certain medications could be made available over the counter, allowing patients to access them more easily at their own expense. This could help reduce costs. This form of self-medication has long been common in the US, where people with certain ailments naturally turn to over-the-counter preparations or potent health foods. How can investors benefit from this trend? We present the shares of Bayer, Nestlé, and PanGenomic Health!
Read
Commented by Armin Schulz on July 17th, 2025 | 07:05 CEST
Bayer, NetraMark, Evotec: How AI Research is accelerating returns and could optimize your portfolio
In 2025, the healthcare industry is undergoing a radical transformation driven by AI and advanced technologies. While pharmaceutical giants struggle with cost pressures and regulatory hurdles, algorithms are revolutionizing drug development by decoding clinical data in record time and enabling personalized therapies. In this period of disruption, innovative strength will determine victory or decline. Three companies are at the forefront of this shift: Bayer, with its broad portfolio; NetraMark, leveraging AI-powered data analysis; and Evotec, with its disruptive research collaborations. Find out what is currently driving these stocks.
Read
Commented by Fabian Lorenz on July 16th, 2025 | 07:25 CEST
WINNING STOCKS for the second half of the year!? Rheinmetall, Bayer, and Hotstock PanGenomic Health
Hard to believe: Bayer shares are among the winners in 2025. And even the news flow is positive. Does the Leverkusen-based company even have a new blockbuster in the pipeline? What do analysts say? PanGenomic Health shares could be among the stars of the second half of the year. With a new health app, the Company is entering a billion-dollar market in the US and benefiting from the Trump administration. If it succeeds in securing market share, the stock should have plenty of upside potential. Analysts believe that the air is getting thinner for Rheinmetall shares. However, it is likely only a matter of time before the EUR 2,000 mark is broken.
Read
Commented by Armin Schulz on July 9th, 2025 | 07:05 CEST
Liver cancer breakthrough fuels billion-dollar market: How Bayer, Vidac Pharma, and Novo Nordisk can now power your portfolio
The pharmaceutical industry is undergoing its biggest upheaval in decades. Megatrends such as cancer treatment, fueled by recent breakthroughs like the EMA approval of the liver cancer therapy Lenvima®/Keytruda®, and revolutionary therapies for diabetes and obesity are generating billion-dollar markets. Those who understand these growth drivers will identify lucrative opportunities. Innovative active ingredients are not only changing medicine but also unlocking exceptional return potential for forward-thinking investors. This dynamic draws attention directly to the strategies of Bayer, Vidac Pharma, and Novo Nordisk.
Read
Commented by Fabian Lorenz on July 8th, 2025 | 07:05 CEST
Rheinmetall above EUR 2,000? Bayer shares exhausted? NetraMark Holdings with lots of upside potential!
It seems only a matter of time before Rheinmetall shares break through the EUR 2,000 barrier. Increasingly, analysts are setting price targets above this mark. And operations are running smoothly, as demonstrated by the latest ammunition order and the Company's participation in the German government's billion-euro investment program. NetraMark, on the other hand, does not have to invest billions in research and development. The AI specialist is still an insider tip. However, the first study is now available, and analysts anticipate over 50% upside potential. In contrast, analysts see the end of the price fireworks at Bayer. Are they right?
Read
Commented by André Will-Laudien on July 4th, 2025 | 07:05 CEST
Lightning on the horizon in the biotech sector: Refinancing on the rise! Keep an eye on Formycon, PanGenomic Health, Bayer, and Novo Nordisk
In the first half of 2025, the biotech sector demonstrated resilience and innovation despite macroeconomic uncertainties. Venture capital financing reached an impressive USD 6.5 billion, with a focus on companies with clinically validated data. Large financing deals such as the USD 365 million for Pathos AI underscore the strategic investor focus on AI and digitalization. The IPO market remains highly selective, but strong stock market debuts such as that of Caris Life Sciences are sending positive signals. At the same time, the M&A sector is booming with billion-dollar acquisitions by pharmaceutical giants such as J&J and Novo. So far in 2025, the biotech sector has demonstrated targeted capital allocation, dynamic consolidation, and growing confidence in medical breakthroughs. Here are a few ideas for a balanced portfolio of opportunities.
Read
Commented by André Will-Laudien on June 30th, 2025 | 07:35 CEST
Takeover fever! Biotech and artificial intelligence boost Evotec, NetraMark Holdings, Novo Nordisk, and Bayer
The biotech sector is currently undergoing an exciting transformation, as big data and artificial intelligence are rapidly changing the way new drugs are discovered, developed, and tested. The use of learning algorithms allows molecular target structures to be identified more quickly and potential active ingredients to be evaluated more efficiently. Start-ups and established players alike are increasingly turning to data-driven platforms to reduce research costs and increase the success rate of clinical trials. As a result, capital is increasingly flowing into companies that use modern data analysis to drive biotechnology. Approaches that enable personalized medicine - treatments precisely tailored to an individual's specific condition - are in particularly high demand. For investors, this represents a promising growth sector with enormous disruptive potential. But who are the most interesting players?
Read
Commented by André Will-Laudien on June 26th, 2025 | 07:00 CEST
New biotech boom ignites: Are Evotec, BioNxt, Bayer, Novo Nordisk, and Formycon poised for the next price surge?
The biotechnology industry is currently experiencing a remarkable renaissance. Innovations in personalized medicine, advances in mRNA technologies, and new therapeutic approaches to cancer and autoimmune diseases are fueling investor interest worldwide. In this dynamic environment, established players such as Evotec and Bayer, as well as specialized up-and-comers like BioNxt and Formycon, are moving into the spotlight of strategic investments. While Evotec scores with its strong partner network, Bayer is working on a realignment with a focus on promising research. BioNxt impresses with a lean business model and promising pipeline products in the field of drug delivery. Formycon, on the other hand, is benefiting from the biosimilar boom and is currently undergoing a turnaround. The industry is highly innovation-driven, and those who bet on the right players could reap above-average rewards.
Read